A detailed history of Vanguard Group Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,529,325 shares of SWTX stock, worth $246 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,529,325
Previous 6,036,542 8.16%
Holding current value
$246 Million
Previous $220 Million 45.86%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$36.5 - $52.5 $18 Million - $25.9 Million
492,783 Added 8.16%
6,529,325 $321 Million
Q4 2023

Feb 14, 2024

BUY
$18.94 - $37.24 $21.1 Million - $41.5 Million
1,114,080 Added 22.63%
6,036,542 $220 Million
Q3 2023

Nov 14, 2023

BUY
$23.12 - $31.38 $477,451 - $648,028
20,651 Added 0.42%
4,922,462 $114 Million
Q2 2023

Aug 14, 2023

BUY
$23.15 - $32.71 $11.4 Million - $16.1 Million
493,284 Added 11.19%
4,901,811 $129 Million
Q1 2023

May 15, 2023

BUY
$24.97 - $34.05 $2.15 Million - $2.93 Million
86,172 Added 1.99%
4,408,527 $113 Million
Q4 2022

Feb 10, 2023

BUY
$21.73 - $28.72 $24.5 Million - $32.3 Million
1,126,310 Added 35.24%
4,322,355 $112 Million
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $10.9 Million - $17.9 Million
451,928 Added 16.47%
3,196,045 $91.2 Million
Q2 2022

Aug 12, 2022

SELL
$18.36 - $60.07 $2.51 Million - $8.22 Million
-136,869 Reduced 4.75%
2,744,117 $67.6 Million
Q1 2022

May 13, 2022

BUY
$48.97 - $65.46 $914,465 - $1.22 Million
18,674 Added 0.65%
2,880,986 $163 Million
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $8,208 - $11,679
154 Added 0.01%
2,862,312 $177 Million
Q3 2021

Nov 12, 2021

BUY
$62.66 - $88.26 $9.78 Million - $13.8 Million
156,091 Added 5.77%
2,862,158 $182 Million
Q2 2021

Aug 13, 2021

BUY
$67.45 - $85.63 $183 Million - $232 Million
2,706,067 New
2,706,067 $223 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.35B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.